Results 291 to 300 of about 143,596 (340)

Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse event reporting system

Bowen Wang, Zheyun Song, Shan Lan, Xiubi Chen, Xida Yan, Xue‐Feng Jiao   +5 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Proton pump inhibitors

Reactions Weekly, 2020
Felice Schnoll-Sussman, Rachel Niec, Philip O. Katz   +2 more
semanticscholar   +3 more sources

Proton-pump inhibitors: understanding the complications and risks

Nature Reviews Gastroenterology and Hepatology, 2017
Peter Malfertheiner, Marino Venerito
exaly   +2 more sources

Proton Pump Inhibitors

Annals of Pharmacotherapy, 2016
Objective: The purpose of this article is to describe the relationship between proton pump inhibitors (PPIs) and symptoms of myopathy based on case reports. Data Sources: A literature search was conducted in PubMed (1946 to June 2016) using MeSH terms proton pump inhibitors, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole ...
Evan W, Colmenares, Ashley L, Pappas
  +6 more sources

Deprescribing proton pump inhibitors

Australian Journal of General Practice, 2022
Proton pump inhibitors (PPIs) are indicated for disorders including peptic ulcer disease and gastro-oesophageal reflux disease; however, they are often used for longer and at higher doses than recommended, or for indications that are not supported by evidence.The aim of this article is to outline evidence-based approaches to deprescribing PPIs.PPIs are
Turner, Justin P., Thompson, Wade, Reeve, Emily, Bell, J. Simon   +3 more
openaire   +4 more sources

Proton pump inhibitors

Reactions Weekly, 2018
G. Lichtenstein
semanticscholar   +3 more sources

Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract—evidence from next‐generation sequencing studies

Alimentary Pharmacology and Therapeutics, 2020
Proton pump inhibitors (PPI) are widely used to treat acid‐related disorders of the upper gastrointestinal tract. However, large observational studies have raised concerns about PPI‐associated adverse events.
L. Macke, C. Schulz, L. Koletzko, P. Malfertheiner   +3 more
semanticscholar   +1 more source

Proton pump inhibitors

Current Opinion in Gastroenterology, 2012
This review summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional deficiencies (B12 and magnesium), rebound acid hypersecretion, acute interstitial nephritis, gastric carcinoid tumor, cardiovascular risk with clopidogrel and PPI coprescription, bone fractures, enteric infections and pneumonia.
openaire   +3 more sources

The effects of proton pump inhibitors on the microbiome in young children

Acta paediatrica, 2020
The use of proton pump inhibitor (PPI) treatments are increasing among paediatric patients worldwide. We aimed to review the effects of PPIs on the microbiome and its associated effect on the gastrointestinal, respiratory and metabolic systems.
E. Levy, Delphine M. Hoang, Y. Vandenplas   +2 more
semanticscholar   +1 more source